What to expect from HER-2 directed therapies in advanced gastric cancer?

被引：1
|
作者：
Dane, Faysal [1 ]
机构：
[1] Marmara Univ, Sch Med, Dept Internal Med, Div Med Oncol, Mimar Sinan Caddesi 41 Ust Kaynarca Fevzicakmak M, Istanbul, Turkey
来源：
MARMARA MEDICAL JOURNAL | 2015年 / 28卷 / 04期
关键词：
Gastric cancer; HER-2/neu; Targeted therapy;
D O I：
10.5472/mmj.87204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma.
引用
收藏
页码：11 / 15
页数：5
相关论文
共 50 条
  • [41] Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways
    Wang, Haiyong
    Lu, Jun
    Tang, Jian
    Chen, Shitu
    He, Kuifeng
    Jiang, Xiaoxia
    Jiang, Weiqin
    Teng, Lisong
    BMC CANCER, 2017, 17
  • [42] Is Helicobacter pylori a Poor Prognostic Factor for HER-2 SISH Positive Gastric Cancer?
    Selcukbiricik, Fatih
    Tural, Deniz
    Erdamar, Sibel
    Buyukunal, Evin
    Demirelli, Fuat
    Serdengecti, Suheyla
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (05) : 3319 - 3322
  • [43] Trastuzumab plus Chemotherapy in Gastric Cancer Overexpressing HER-2 and EGFR: A Case Report
    Al-Batran, Salah-Eddin
    Ruppert, Margarete
    Jaeger, Elke
    ONKOLOGIE, 2011, 34 (1-2): : 42 - 45
  • [44] HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma
    Movagharnejad, Kourosh
    Sharbatdaran, Majid
    Sheffaee, Shahryar
    Kashifard, Mehrdad
    Sedaghat, Sadegh
    INTERNATIONAL JOURNAL OF MOLECULAR AND CELLULAR MEDICINE, 2013, 2 (04) : 199 - 203
  • [45] Clinical significance of CD166 and HER-2 in different types of gastric cancer
    Leila Moradi
    Fatemeh Tajik
    Leili Saeednejad Zanjani
    Mahshid Panahi
    Elmira Gheytanchi
    Zahra Sadat Biabanaki
    Golnaz Ensieh Kazemi-Sefat
    Farideh Hashemi
    Masoumeh Dehghan Manshadi
    Zahra Madjd
    Clinical and Translational Oncology, 2024, 26 : 664 - 681
  • [46] HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer
    Inui, T.
    Asakawa, A.
    Morita, Y.
    Mizuno, S.
    Natori, T.
    Kawaguchi, A.
    Murakami, M.
    Hishikawa, Y.
    Inui, A.
    JOURNAL OF INTERNAL MEDICINE, 2006, 260 (05) : 484 - 487
  • [47] Clinical significance of CD166 and HER-2 in different types of gastric cancer
    Moradi, Leila
    Tajik, Fatemeh
    Zanjani, Leili Saeednejad
    Panahi, Mahshid
    Gheytanchi, Elmira
    Biabanaki, Zahra Sadat
    Kazemi-Sefat, Golnaz Ensieh
    Hashemi, Farideh
    Manshadi, Masoumeh Dehghan
    Madjd, Zahra
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (03) : 664 - 681
  • [48] The expression and clinical significance of PDCD4 and Her-2 in human gastric cancer
    Yang, Yuelou
    Jiang, Xiangjun
    Li, Dong
    Wang, Feiyan
    Yang, Qun
    Li, Bin
    EUROPEAN JOURNAL OF INFLAMMATION, 2019, 17
  • [49] Her-2 in gastroesophageal cancer: pathobiology, diagnostic and therapeutic implications
    Birner, P.
    Schoppmann, S. F.
    EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA, 2011, 43 (03): : 162 - 167
  • [50] Maintenance treatment in advanced HER2-negative gastric cancer
    Y. Yao
    R. Deng
    D. Liao
    H. Xie
    J. Zuo
    Y. Jia
    F. Kong
    Clinical and Translational Oncology, 2020, 22 : 2206 - 2212
12345